-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor-in-ChiefEnzyme America has 120 million diabetic patients in China, and 90% of the endogenous sugar output comes from the liver.
Traditional diabetes drugs are not effective in reducing fasting blood sugar
.
The abnormal activity of hepatic gluconeogenesis is one of the main reasons for the persistently high blood sugar level in diabetic patients, and it is also the main culprit of fasting hyperglycemia in patients
.
Hepatic gluconeogenesis mediated by the key CREB/CRTC2 transcriptional complex in the liver is one of the main pathways of the body's blood glucose elevation
.
Glucagon activates cyclic adenosine monophosphate-responsive element-binding protein (CREB) in hepatocytes through the 3,5-cyclic adenosine monophosphate (cAMP) signaling pathway, thereby upregulating the key enzyme glucose-6- Expression of phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK)
.
After glucagon binds to the glucagon receptor on the liver cell membrane, it inhibits the activity of SIK2 through the cAMP-PKA cascade reaction, and dephosphorylates CREB-regulated transcriptional coactivator 2 (CRTC2) into the nucleus and binds to CREB.
CREB-controlled gene expression is upregulated
.
CREB/CRTC2 protein-protein interaction inhibitors can regulate the expression of downstream gluconeogenesis-related genes and reduce fasting blood glucose by inhibiting gluconeogenesis
.
On January 11, 2022, researcher Liu Hong from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, together with Prof.
Liu Yu from Fudan University and Prof.
Hu Lihong from Nanjing University of Traditional Chinese Medicine published a paper entitled A propolis-derived small molecule ameliorates metabolic syndrome in obese mice by Nature Communications.
The research paper targeting the CREB/CRTC2 transcriptional complex has made important progress in the research of CREB/CRTC2 protein-protein interaction inhibitors, a new target for diabetes, and reports the lead compounds of CREB/CRTC2 protein interaction inhibitors, a new target for diabetes
.
For the first time, the researchers verified that the main component of Brazilian propolis, artepillin C (artepillin C), can inhibit the CREB/CRTC2 protein-protein interaction, and at the same time reduce the fasting blood glucose, increase insulin sensitivity, and reduce the blood lipid levels
.
Through in vitro and in vivo experiments, it was verified that the natural product Apideline C binds to CREB, blocks the CREB/CRTC2 protein-protein interaction, regulates the expression of gluconeogenesis-related genes, and then exerts the therapeutic effect of reducing fasting blood glucose
.
In order to improve the inhibitory effect and druggability of the natural product Apideline C on the CREB/CRTC2 protein-protein interaction, the researchers comprehensively used a variety of structural optimization and design strategies in medicinal chemistry to conduct the CREB/CRTC2 protein-protein interaction inhibitor.
Structure-activity relationship study and pharmacological activity evaluation
.
Through multiple rounds of structural optimization, it was found that the lead compound A57 targeting the CREB/CRTC2 protein-protein interaction inhibitor has a strong inhibitory effect on the CREB/CRTC2 protein-protein interaction with IC50 reaching 0.
74 μM, which is a natural product of apidiline 30 times the inhibitory activity of C; Compound A57 significantly inhibited the transcription levels of gluconeogenesis rate-limiting enzyme genes Pck1 and G6pc; oral administration significantly reduced fasting blood glucose and blood lipid levels in db/db mice, but not in CRTC2 KO mice The glucose activity further verified the hypoglycemic mechanism of the lead compound A57
.
This research work provides a new target and a new treatment strategy for diabetic patients with poor fasting blood glucose treatment effect.
The discovery of the lead compound A57 has laid a research foundation for the development of class I diabetes drugs with China's independent intellectual property rights
.
Chen Yaqiong from Fudan University and Wang Jiang from Shanghai Institute of Materia Medica, Chinese Academy of Sciences are the co-first authors of the article; Professor Liu Xun from Fudan University, Professor Liu Hong from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Professor Hu Lihong from Nanjing University of Traditional Chinese Medicine are the joint correspondents of the article author
.
Full text link: https:// Publisher: 11th reprint notice [Non-original article] The copyright of this article belongs to the author of the article, personal reposting and sharing are welcome, and it is prohibited without permission For reprinting, the author has all legal rights, and offenders will be held accountable
.
Traditional diabetes drugs are not effective in reducing fasting blood sugar
.
The abnormal activity of hepatic gluconeogenesis is one of the main reasons for the persistently high blood sugar level in diabetic patients, and it is also the main culprit of fasting hyperglycemia in patients
.
Hepatic gluconeogenesis mediated by the key CREB/CRTC2 transcriptional complex in the liver is one of the main pathways of the body's blood glucose elevation
.
Glucagon activates cyclic adenosine monophosphate-responsive element-binding protein (CREB) in hepatocytes through the 3,5-cyclic adenosine monophosphate (cAMP) signaling pathway, thereby upregulating the key enzyme glucose-6- Expression of phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK)
.
After glucagon binds to the glucagon receptor on the liver cell membrane, it inhibits the activity of SIK2 through the cAMP-PKA cascade reaction, and dephosphorylates CREB-regulated transcriptional coactivator 2 (CRTC2) into the nucleus and binds to CREB.
CREB-controlled gene expression is upregulated
.
CREB/CRTC2 protein-protein interaction inhibitors can regulate the expression of downstream gluconeogenesis-related genes and reduce fasting blood glucose by inhibiting gluconeogenesis
.
On January 11, 2022, researcher Liu Hong from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, together with Prof.
Liu Yu from Fudan University and Prof.
Hu Lihong from Nanjing University of Traditional Chinese Medicine published a paper entitled A propolis-derived small molecule ameliorates metabolic syndrome in obese mice by Nature Communications.
The research paper targeting the CREB/CRTC2 transcriptional complex has made important progress in the research of CREB/CRTC2 protein-protein interaction inhibitors, a new target for diabetes, and reports the lead compounds of CREB/CRTC2 protein interaction inhibitors, a new target for diabetes
.
For the first time, the researchers verified that the main component of Brazilian propolis, artepillin C (artepillin C), can inhibit the CREB/CRTC2 protein-protein interaction, and at the same time reduce the fasting blood glucose, increase insulin sensitivity, and reduce the blood lipid levels
.
Through in vitro and in vivo experiments, it was verified that the natural product Apideline C binds to CREB, blocks the CREB/CRTC2 protein-protein interaction, regulates the expression of gluconeogenesis-related genes, and then exerts the therapeutic effect of reducing fasting blood glucose
.
In order to improve the inhibitory effect and druggability of the natural product Apideline C on the CREB/CRTC2 protein-protein interaction, the researchers comprehensively used a variety of structural optimization and design strategies in medicinal chemistry to conduct the CREB/CRTC2 protein-protein interaction inhibitor.
Structure-activity relationship study and pharmacological activity evaluation
.
Through multiple rounds of structural optimization, it was found that the lead compound A57 targeting the CREB/CRTC2 protein-protein interaction inhibitor has a strong inhibitory effect on the CREB/CRTC2 protein-protein interaction with IC50 reaching 0.
74 μM, which is a natural product of apidiline 30 times the inhibitory activity of C; Compound A57 significantly inhibited the transcription levels of gluconeogenesis rate-limiting enzyme genes Pck1 and G6pc; oral administration significantly reduced fasting blood glucose and blood lipid levels in db/db mice, but not in CRTC2 KO mice The glucose activity further verified the hypoglycemic mechanism of the lead compound A57
.
This research work provides a new target and a new treatment strategy for diabetic patients with poor fasting blood glucose treatment effect.
The discovery of the lead compound A57 has laid a research foundation for the development of class I diabetes drugs with China's independent intellectual property rights
.
Chen Yaqiong from Fudan University and Wang Jiang from Shanghai Institute of Materia Medica, Chinese Academy of Sciences are the co-first authors of the article; Professor Liu Xun from Fudan University, Professor Liu Hong from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Professor Hu Lihong from Nanjing University of Traditional Chinese Medicine are the joint correspondents of the article author
.
Full text link: https:// Publisher: 11th reprint notice [Non-original article] The copyright of this article belongs to the author of the article, personal reposting and sharing are welcome, and it is prohibited without permission For reprinting, the author has all legal rights, and offenders will be held accountable
.
